Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects

被引:45
作者
Mercado, Moises [1 ,2 ]
Meigar, Virgilio [2 ]
Salame, Latife [1 ]
Cuenca, Dalia [3 ]
机构
[1] Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl S21, IMSS, Expt Endocrinol Unit, Mexico City, DF, Mexico
[2] Amer British Cowdray Med Ctr, Neurol Ctr, Mexico City, DF, Mexico
[3] Amer British Cowdray Med Ctr, Dept Med, Mexico City, DF, Mexico
来源
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2017年 / 64卷 / 07期
关键词
Nonfunctioning pituitary adenomas; Gonadotropinomas; Null cell adenomas; LH; FSH; Hypopituitarism; TUMOR-TRANSFORMING GENE; QUALITY-OF-LIFE; NATURAL-HISTORY; TRANSSPHENOIDAL SURGERY; RADIATION-THERAPY; CARNEY COMPLEX; CELL ADENOMAS; TYPE-1; MEN1; FOLLOW-UP; MACROADENOMAS;
D O I
10.1016/j.endinu.2017.05.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinically non-functioning pituitary adenomas (NFPAs) are among the most common tumors in the sellar region. These lesions do not cause a hormonal hypersecretion syndrome, and are therefore found incidentally (particularly microadenomas) or diagnosed based on compressive symptoms such as headache and visual field defects, as well as clinical signs of pituitary hormone deficiencies. Immunohistochemically, more than 45% of these adenomas stain for gonadotropins or their subunits and are therefore called gonadotropinomas, while 30% of them show no immunostaining for any hormone and are known as null cell adenomas. The diagnostic approach to NFPAs should include visual field examination, an assessment of the integrity of all anterior pituitary hormone systems, and magnetic resonance imaging of the sellar region to define tumor size and extension. The treatment of choice is transsphenoidal resection of the adenoma, which in many instances cannot be completely accomplished. The recurrence rate after surgery may be up to 30%. Persistent or recurrent adenomas are usually treated with radiation therapy. In a small proportion of these cases, drug treatment with dopamine agonists and, to a lesser extent, somatostatin analogs may achieve reduction or at least stabilization of the tumor. (c) 2017 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:384 / 395
页数:12
相关论文
共 118 条
[1]   Epidemiology and etiopathogenesis of pituitary adenomas [J].
Aflorei, Elena D. ;
Korbonits, Marta .
JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (03) :379-394
[2]   The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study [J].
Agustsson, Tomas Thor ;
Baldvinsdottir, Tinna ;
Jonasson, Jon G. ;
Olafsdottir, Elinborg ;
Steinthorsdottir, Valgerdur ;
Sigurdsson, Gunnar ;
Thorsson, Arni V. ;
Carroll, Paul V. ;
Korbonits, Marta ;
Benediktsson, Rafn .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 173 (05) :655-664
[3]  
[Anonymous], 2004, WHO CLASSIFICATION T
[4]   DYNAMICS OF PROLACTIN SECRETION IN PATIENTS WITH HYPOPITUITARISM AND PITUITARY MACROADENOMAS [J].
ARAFAH, BM ;
NEKL, KE ;
GOLD, RS ;
SELMAN, WR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3507-3512
[5]   Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination [J].
Arita, Kazunori ;
Tominaga, Atsushi ;
Sugiyama, Kazuhiko ;
Eguchi, Kuniki ;
Iida, Koji ;
Sumida, Masayuki ;
Migita, Keisuke ;
Kurisu, Kaoru .
JOURNAL OF NEUROSURGERY, 2006, 104 (06) :884-891
[6]  
Asa SL, 2008, ARCH PATHOL LAB MED, V132, P1231, DOI 10.1043/1543-2165(2008)132[1231:PPPWDT]2.0.CO
[7]  
2
[8]   Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics [J].
Balogun, James A. ;
Monsalves, Eric ;
Juraschka, Kyle ;
Parvez, Kashif ;
Kucharczyk, Walter ;
Mete, Ozgur ;
Gentili, Fred ;
Zadeh, Gelareh .
ENDOCRINE PATHOLOGY, 2015, 26 (01) :63-70
[9]   Isolated Pupil-Involving Third Nerve Palsy as the First Presentation of Sarcoidosis [J].
Bansal, Shveta ;
Yin, Kun ;
Vishwanath, Mandagere ;
Doran, Helen ;
Laitt, Roger ;
Ansons, Alec .
NEURO-OPHTHALMOLOGY, 2014, 38 (05) :278-280
[10]   Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints [J].
Bartkova, Jirina ;
Rezaei, Nousin ;
Liontos, Michalis ;
Karakaidos, Panagiotis ;
Kletsas, Dimitris ;
Issaeva, Natalia ;
Vassiliou, Leandros-Vassilios F. ;
Kolettas, Evangelos ;
Niforou, Katerina ;
Zoumpourlis, Vassilis C. ;
Takaoka, Munenori ;
Nakagawa, Hiroshi ;
Tort, Frederic ;
Fugger, Kasper ;
Johansson, Fredrik ;
Sehested, Maxwell ;
Andersen, Claus L. ;
Dyrskjot, Lars ;
Orntoft, Torben ;
Lukas, Jiri ;
Kittas, Christos ;
Helleday, Thomas ;
Halazonetis, Thanos D. ;
Bartek, Jiri ;
Gorgoulis, Vassilis G. .
NATURE, 2006, 444 (7119) :633-637